Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,769
archived clinical trials in
Migraine Headaches

Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 11
mi
from
Cleveland, OH
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 11
mi
from
Cleveland, OH
Click here to add this to my saved trials
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site
mi
from
Columbus, OH
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site
mi
from
Columbus, OH
Click here to add this to my saved trials
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site
mi
from
Oklahoma City, OK
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10183
mi
from
Philadelphia, PA
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10183
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 12467
mi
from
Mount Pleasant, SC
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 12467
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 13560
mi
from
Bristol, TN
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 13560
mi
from
Bristol, TN
Click here to add this to my saved trials
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 084
mi
from
Memphis, TN
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 084
mi
from
Memphis, TN
Click here to add this to my saved trials
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 1310
mi
from
Nashville, TN
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 1310
mi
from
Nashville, TN
Click here to add this to my saved trials
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10372
mi
from
Arlington, TX
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10372
mi
from
Arlington, TX
Click here to add this to my saved trials
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10405
mi
from
Austin, TX
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10405
mi
from
Austin, TX
Click here to add this to my saved trials
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 12222
mi
from
Charlottesville, VA
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 12222
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 1339
mi
from
Roanoke, VA
Assessment of LBR-101 In Chronic Migraine
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 1339
mi
from
Roanoke, VA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 1327
mi
from
Gilbert, AZ
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 1327
mi
from
Gilbert, AZ
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 043
mi
from
Scottsdale, AZ
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 043
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site
mi
from
Little Rock, AR
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10802
mi
from
Phoenix, AR
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10802
mi
from
Phoenix, AR
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10358
mi
from
Anaheim, CA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10358
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 1326
mi
from
Fullerton, CA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 1326
mi
from
Fullerton, CA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10147
mi
from
Long Beach, CA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10147
mi
from
Long Beach, CA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10665
mi
from
Oceanside, CA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10665
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 69
mi
from
San Francisco, CA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 69
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 4
mi
from
Stanford, CA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 4
mi
from
Stanford, CA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10129
mi
from
Walnut Creek, CA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10129
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 1344
mi
from
Boulder, CO
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 1344
mi
from
Boulder, CO
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 13071
mi
from
Stamford, CT
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 13071
mi
from
Stamford, CT
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10369
mi
from
DeLand, FL
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10369
mi
from
DeLand, FL
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 11141
mi
from
Hialeah, FL
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 11141
mi
from
Hialeah, FL
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 12535
mi
from
Hollywood, FL
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 12535
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 021
mi
from
Jacksonville, FL
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 021
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10715
mi
from
Maitland, FL
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10715
mi
from
Maitland, FL
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10269
mi
from
Orlando, FL
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10269
mi
from
Orlando, FL
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10064
mi
from
Ormond Beach, FL
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10064
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 140
mi
from
Port Orange, FL
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 140
mi
from
Port Orange, FL
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10593
mi
from
South Miami, FL
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10593
mi
from
South Miami, FL
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 096
mi
from
Atlanta, GA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 096
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 01
mi
from
Decatur, GA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 01
mi
from
Decatur, GA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 13535
mi
from
Douglasville, GA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 13535
mi
from
Douglasville, GA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10380
mi
from
Evansville, IN
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10380
mi
from
Evansville, IN
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 1334
mi
from
Lenexa, KA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 1334
mi
from
Lenexa, KA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10538
mi
from
Brockton, MA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10538
mi
from
Brockton, MA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site CHACHAR
mi
from
New Bedford, MA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site CHACHAR
mi
from
New Bedford, MA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 51
mi
from
Springfield, MA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 51
mi
from
Springfield, MA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 603
mi
from
Watertown, MA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 603
mi
from
Watertown, MA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 115
mi
from
Worcester, MA
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 115
mi
from
Worcester, MA
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 098
mi
from
Ann Arbor, MI
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 098
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 114
mi
from
Kalamazoo, MI
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 114
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 39
mi
from
Golden Valley, MN
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 39
mi
from
Golden Valley, MN
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 13534
mi
from
Kansas City, MO
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 13534
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 10552
mi
from
Saint Louis, MO
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 10552
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated:  4/2/2018
Teva Investigational Site 13536
mi
from
Springfield, MO
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine
Status: Enrolling
Updated: 4/2/2018
Teva Investigational Site 13536
mi
from
Springfield, MO
Click here to add this to my saved trials